MigraineMind research summary

Impact of sphenopalatine ganglion blocks on high-frequency episodic and chronic migraine: A retrospective study.

Headache | 2026

Clinical trial
AuthorsVinciguerra L, Brusaferri F, Zito A, Saponara R, Paletta R
JournalHeadache
Publication year2026
PubMed ID42928999

Summary

This study looked at the effectiveness and safety of sphenopalatine ganglion blocks for migraines. This procedure uses a special catheter to deliver local anesthetics directly to a specific nerve area. The sphenopalatine ganglion is involved in headache disorders. Researchers aimed to find out how well this treatment works for people with high-frequency episodic or chronic migraines. They conducted a retrospective study at a single center, examining patients' outcomes. The study included patients who sometimes overused migraine medications. Results showed that this treatment could help reduce migraine frequency and improve patient quality of life. However, more research is needed to confirm these findings. Currently, there are no controlled trials specifically assessing this treatment using the dedicated catheter. Overall, the study suggests that this method may be a promising option for migraine management. Clinical relevance: This research indicates that sphenopalatine ganglion blocks could effectively reduce migraine frequency, offering new hope for patients struggling with chronic or high-frequency migraines.

Key Learning Points

  • Sphenopalatine ganglion blocks may effectively reduce the frequency of migraines for patients with chronic or high-frequency episodes.
  • This treatment could improve the overall quality of life for individuals suffering from migraines.
  • The procedure involves delivering local anesthetics directly to a specific nerve area using a special catheter.
  • Current findings are based on a single-center retrospective study, highlighting the need for further research.
  • No controlled trials have yet assessed the effectiveness of this treatment with the dedicated catheter, indicating a gap in the evidence.

Research Informatics

SINGLE-ARM TRIAL

Preliminary findings suggest potential migraine symptom improvement.

conditionHigh-frequency episodic and chronic migraine
sample Size30
populationPatients with high-frequency episodic or chronic migraine
follow Up13 months
primary OutcomeReduction in Monthly Migraine Days and Monthly Acute Migraine Medications
safetySeventeen nonsevere adverse events, mostly local discomfort

Related migraine research topics

Original research

Read the original publication and review its full methods and findings on PubMed.

MigraineMind is an educational resource designed to complement—not replace—the original scientific literature or clinical judgement. This page is an AI-generated summary of the available paper information and may contain errors. Please consult the original publication.